-
-
-
-
-
-
-
BofA on PTC Therapeutics (PTCT): 'See opportunity for >$2bn in global Sephience sales'
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $55 at Goldman Sachs
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $50 at Goldman Sachs
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Lowered to $63 at Jefferies
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Tops Q2 EPS by 23c, provides guidance
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Halted, News Pending
-
430,616 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

